Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

Roche’s Vabysmo Receives EU Approval
Roche’s Vabysmo Receives EU Approval
The European Commission has approved Roche’s Vabysmo (faricimab) for the treatment of neovascular or ‘wet’ age-related macular degeneration and visual impairment due to diabetic macular edema...
Researchers identify molecular mechanisms leading to zika-associated microcephaly
Researchers identify molecular mechanisms leading to zika-associated microcephaly
Proteomic analysis suggests zika virus causes alterations in the expression of proteins linked to the metabolism of developing neural cells, and proteins associated with the maturation of oligodend...
Rheumatoid arthritis drug effective against myasthenia
Rheumatoid arthritis drug effective against myasthenia
Early intervention with rituximab, a drug used in the treatment of rheumatoid arthritis (RA), can reduce the risk of deterioration in myasthenia gravis, an autoimmune disease that causes loss of mu...
Nearly one in 10 in the US reports having depression
Nearly one in 10 in the US reports having depression
Increases in depression without commensurate increases in treatment are widespread, reports a study conducted at Columbia University Mailman School of Public Health and City University of...
CDC Guidance Considers Tecovirimat in Monkeypox
CDC Guidance Considers Tecovirimat in Monkeypox

The Centers for Disease Control and Prevention (CDC) has provided guidelines on using Siga Technologies’ Tpoxx (tecovirimat) in treating monkeypox.

Phase 3 readout sets up filings for Pfizer’s meningitis vaccine
Phase 3 readout sets up filings for Pfizer’s meningitis vaccine
Pfizer’s close-fought contest with GSK to bring a next-generation meningitis vaccine to market has entered the final rounds, with the former ahead on points following the readout of a pivotal pha...
AstraZeneca scores phase 3 win with novel complement drug danicopan
AstraZeneca scores phase 3 win with novel complement drug danicopan
Prospects for AstraZeneca’s oral Factor D inhibitor danicopan were looking poor after it failed a phase 2 trial in a rare kidney disease in 2020, but a new readout could reinvigorate the drug. ...
Jasper Therapeutics’ JSP191 Gains Fast Track Designation
Jasper Therapeutics’ JSP191 Gains Fast Track Designation
Jasper Therapeutics’ investigational monoclonal antibody JSP191 has gained Fast Track status from the FDA for the treatment of patients with severe combined immunodeficiency (SCID) undergoing all...
WHO denounces GSK-VIR, Regeneron COVID drugs following Lancet criticism
WHO denounces GSK-VIR, Regeneron COVID drugs following Lancet criticism
The Lancet Commission published a long critical of the World Health Organizationof the response to the COVID-19 pandemic. The WHO, in turn, welcomed the Commission’s recommendations, but offered...
Mirati Releases Promising Adagrasib Results for Advanced Colorectal Cancer
Mirati Releases Promising Adagrasib Results for Advanced Colorectal Cancer
Therapy shows positive clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients who have a KRASG12C mutation. ...
Pfizer Begins Phase 3 Clinical Trial to Evaluate mRNA-Based Influenza Vaccine
Pfizer Begins Phase 3 Clinical Trial to Evaluate mRNA-Based Influenza Vaccine
Pfizer has announced that the first participants have been dosed in a phase 3 clinical trial evaluating the efficacy, immunogenicity, safety and tolerability of its investigational quadrivalent mod...
FDA Approves Spevigo for Treatment of Generalized Pustular Psoriasis Flares in Adults
FDA Approves Spevigo for Treatment of Generalized Pustular Psoriasis Flares in Adults

Boehringer Ingelheim’s monoclonal antibody inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for this indication.

Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand